Contents

Key Findings

1. Scientific Background

HBV is a small, enveloped, partially double-stranded DNA virus whose replication depends on reverse transcription. The absence of a conventional proofreading function during reverse transcription promotes genetic variation, while immune selection, host movement, transmission networks, recombination and demographic history shape which lineages persist. Genotypes are conventionally based largely on whole-genome divergence, and subgenotypes require coherent phylogenetic clustering and characteristic sequence divergence. Classification continues to evolve; consequently, labels should be interpreted alongside genomic coverage, reference sequences and the rules used when a study was performed.^1–3

Genotype is not the same as disease stage, viral load, HBeAg status, treatment response or prognosis. These biological and clinical features may be associated in some populations, but they are also shaped by age at acquisition, sex, host genetics, immune state, coinfections, metabolic factors, alcohol, aflatoxin exposure, duration of infection, viral variants and access to care. Ethiopian genotype data therefore have immediate value for molecular surveillance and assay evaluation, but cannot by themselves determine an individual patient’s treatment or outcome.

Ethiopia’s location and human history make it especially informative for African HBV phylogeography. Yet geography also creates a major interpretive challenge. A multicentre blood-donor series spanning five regions provides a different window from a single-hospital cohort in Gondar, a pregnant-women sample in Amhara, or an HIV clinic population. None should be treated as a random miniature of the entire country.

1.1 Molecular foundations of HBV diversity

The HBV genome is only about 3.2 kilobases long, yet it contains four extensively overlapping open reading frames—polymerase, surface, core/precore and X. This compression has major evolutionary consequences. A nucleotide substitution in one genomic region may alter more than one protein because the polymerase and surface genes overlap. Selection acting on an envelope epitope may therefore influence polymerase sequence, and antiviral selection in polymerase may create a linked change in surface antigen. Molecular findings must consequently be interpreted at the genome level rather than as isolated letters in a mutation list.

HBV replication begins when relaxed circular DNA is delivered to the hepatocyte nucleus and repaired into covalently closed circular DNA. Transcription from cccDNA generates viral RNAs, including pregenomic RNA, which is reverse-transcribed inside nucleocapsids. Reverse transcription is error-prone compared with replication by high-fidelity cellular DNA polymerases. The resulting quasispecies is a population of closely related variants—not a single immutable sequence. Immune pressure, antiviral exposure, transmission bottlenecks and stochastic drift determine which variants become detectable in blood.

Genotypes represent deep evolutionary divisions and are generally assigned using full-genome divergence and phylogenetic clustering. Subgenotypes describe coherent branches within a genotype, but their designation is more vulnerable to disagreement when only short fragments or few sequences are available. Recombination further complicates classification: different regions of the same genome may cluster with different ancestral genotypes. For this reason, a subgenotype claim based on a partial S-gene sequence carries less taxonomic certainty than one supported by multiple epidemiologically unrelated complete genomes and recombination-aware phylogenetics.

1.2 What genotype distribution can—and cannot—tell us

Genotype distribution can reveal historical and contemporary connections between viral populations. A1 is strongly associated with African evolutionary history and later dispersal beyond the continent, whereas genotype D has a broad distribution across northern Africa, the Mediterranean, the Middle East and parts of Asia. The coexistence of A1 and multiple D lineages in Ethiopia is therefore consistent with the country’s position between eastern sub-Saharan Africa, the Horn of Africa and trans-Red Sea or northern corridors. This interpretation is biologically plausible, but present-day sequence surveys alone cannot date introductions or identify a specific migration event.

Molecular geography is not equivalent to ethnic, linguistic or political geography. Viruses move through families, sexual networks, medical exposures, migration, trade and population displacement. A sequence sampled in one region may have been acquired elsewhere. Robust phylogeography requires sampling location, residence history, travel or birthplace metadata where ethically appropriate, collection date, evolutionary-clock analysis and comparison with sufficiently dense regional reference sequences.

2. Review Approach and Evidentiary Rules

This report prioritized peer-reviewed human studies conducted in Ethiopia that reported an HBV genotype, subgenotype, phylogenetic lineage or assay-defined genotype pattern. Major international reviews were used to frame classification and clinical interpretation. Searches and cross-reference checks emphasized PubMed-indexed records, journal full texts and DOI-linked publisher pages. Evidence available through the stated review date was considered.

For every Ethiopian study, the review distinguished the recruited population from the molecularly characterized subset. Sequence-based studies were given the greatest weight for lineage interpretation. Whole-genome phylogenetics was treated as more informative for subgenotype designation and recombination than short-fragment sequencing. OBI-enriched cohorts were separated because selection on HBsAg negativity and HBV-DNA detectability produces a biologically distinct sample. RFLP-defined mixed patterns were also separated because banding patterns may detect or infer combinations differently from consensus Sanger sequences or deep sequencing.

3. The Ethiopian Molecular Evidence

Reading note: This table intentionally avoids a grand total. Some publications analyze selected subsets or later expansions of related source cohorts; combining them would create false precision and could double-count participants or specimens.

3.1 The multicentre foundation

The strongest early geographic overview came from 391 HBsAg-positive blood-donor specimens collected across five Ethiopian regions. S/pol amplification and phylogenetic analysis successfully characterized 371. Genotype A accounted for 291 and genotype D for 80. The importance of this study lies not only in its size but also in its geographic breadth and sequence-based assignments. It established the enduring central observation: genotype A, mostly A1, is widespread, while genotype D is a substantial minority with internal diversity.⁴

Nevertheless, 78.4% is the proportion among successfully characterized isolates in that donor series—not the prevalence of genotype A among all Ethiopians, all people with HBV, or even all HBsAg-positive donors nationally. Blood-donor eligibility, regional contribution, collection period and amplification success all define the denominator.

3.2 Whole genomes reveal more than short fragments

A subsequent analysis characterized 29 complete genomes originating from five Ethiopian regions. Ten were A1 and 19 were genotype D. Fifteen D genomes formed a well-supported cluster with greater than 4% divergence from other recognized D subgenotypes and nine reported amino-acid signatures across surface, polymerase and X proteins; the authors provisionally designated this cluster D10. The study also identified two recombinants, four pre-S deletion variants, frequent G1896A among D strains, and basal core promoter A1762T/G1764A in subsets of both major genotypes.⁵

These findings demonstrate why whole genomes matter. Short S or S/pol fragments can classify major genotypes reasonably well but may miss recombination breakpoints, obscure genome-wide relatedness or overstate the certainty of a subgenotype label. The 29 genomes should therefore be understood as a deep characterization of selected isolates, not another independent prevalence survey.

3.3 Evidence across specific populations

Southern Ethiopian blood-donor evidence again detected A and D, with genotype A predominating. The Amhara pregnancy study found A in 39 of 46 successfully sequenced samples and D in seven; all A isolates were classified as A1, while the D set included D2, D4 and D10 assignments. These studies reinforce the A/A1 signal, but neither represents the general population.⁷¹¹

The large northwestern molecular study broadened the picture: genotype A represented 61.1%, D 38.3% and E 0.6% of its phylogenetically analyzed sequences. Within A, 99.1% were assigned to A1 and 0.9% to A9. Within D, D2 was most common (63.8%), followed by D4 (21.7%), D1 (8.7%), D3 (4.3%) and D10 (1.4%).¹⁰ This is valuable evidence for genuine D diversity and occasional E detection, but its combined clinical strata do not constitute probability sampling of Ethiopia.

4. Interpreting Ethiopia’s HBV Lineages

4.1 Genotype A and the dominance of A1

The most stable conclusion across conventional sequencing studies is not an exact percentage but a hierarchy: HBV/A is generally first, and A1 overwhelmingly explains the genotype-A signal. A1 is deeply rooted in African HBV diversity and has been used to examine historical movements within and beyond Africa.¹⁴ Ethiopian A1 sequences add an important northeastern/eastern African component to this phylogeographic record.

A rare A9 assignment in the northwestern dataset should be treated as a signal for confirmation rather than as evidence that A9 is established at meaningful prevalence. Subgenotype nomenclature—especially within genotype A—has a history of revision and misclassification. Full genomes, contemporary reference sets and transparent tree support are essential when rare assignments could alter geographic interpretation.

4.2 Genotype D: less common overall, more heterogeneous internally

Genotype D is consistently the second major lineage in broad Ethiopian sequencing studies, but it is not a single homogeneous block. D2 appears prominent, while D1, D3 and D4 have also been reported. The proposed D10 cluster is especially relevant to Ethiopia. This diversity may reflect multiple introductions, long-standing local evolution, migration corridors and recombination; current cross-sectional samples cannot resolve their relative contributions.

The phrase “genotype D is associated with occult infection” must be used cautiously. D predominated in two Gondar OBI-enriched cohorts, which is an important reproducible local observation. But shared geography, selection algorithms, low viral loads, assay characteristics, pregnancy or HIV status could influence the pattern. Demonstrating an independent genotype effect would require adequately powered comparative studies with the same OBI definition, sensitive assays, representative sampling and adjustment for confounding.

4.3 Genotype E, recombination and apparent mixtures

Genotype E is dominant across much of western Africa but appears uncommon in Ethiopian sequence-based reports. Its detection at 0.6% in the northwestern study is biologically plausible and epidemiologically noteworthy, yet insufficient to define a stable Ethiopian reservoir. Movement between regions and countries can introduce lineages without creating broad endemicity.

Recombination is a separate phenomenon from coinfection. A recombinant genome contains segments with different evolutionary ancestry; a mixed infection contains more than one viral genotype in the same host. Consensus sequencing can miss minority lineages, while RFLP may infer multiple patterns that require sequence confirmation. These terms should never be used interchangeably.

4.4 A population-stratified interpretation

Blood-donor studies are especially useful for monitoring viruses circulating among apparently healthy adults, but donor selection excludes many people with known illness, anaemia, recent risk exposures or other ineligibility. Pregnancy cohorts provide information essential to prevention of mother-to-child transmission, yet contain only women within a limited reproductive-age range. HIV cohorts are indispensable for studying coinfection, occult infection and treatment-associated selection, but immunological status and exposure to antiretroviral drugs distinguish them from HBV-monoinfected populations. Liver-disease cohorts enrich for clinically advanced phenotypes and cannot estimate lineage distribution among asymptomatic infection.

These differences are not merely statistical inconveniences; they change the biological question. A lineage common among successfully sequenced blood donors may be less common in a hospital OBI cohort. That contrast could reflect genuine genotype biology, geographic clustering, age structure, viral-load-dependent amplification or selection into care. Only a study that samples these populations concurrently with standardized methods can distinguish these explanations.

4.5 Temporal change and contemporary surveillance

Most available Ethiopian studies are cross-sectional and represent different collection periods. Their percentages should not automatically be arranged as a time trend. A change between two publications may arise from geography, population composition, assay or successful-amplification thresholds rather than replacement of one lineage by another. Demonstrating temporal change requires repeated sampling from a stable surveillance frame using comparable laboratory and analytic methods.

Nevertheless, continued surveillance is warranted. Population movement, expansion of vaccination, changing medical practices, antiviral use and transmission prevention can alter which viral lineages and variants are observed. A national sequence repository linked to year and region of collection would allow Ethiopia to distinguish true evolutionary change from study-to-study noise.

5. Occult HBV Infection: A Distinct Evidence Stratum

Occult HBV infection is defined by the persistence of replication-competent HBV DNA—classically in the liver, with or without intermittently detectable blood HBV DNA—in a person who tests negative for HBsAg. Because blood DNA is often very low and intermittent, prevalence estimates depend heavily on specimen type, sampled volume, extraction efficiency, assay sensitivity, repeat testing and contamination control.¹⁵

Among 291 HIV-positive/HBsAg-negative participants in Gondar, 115 were anti-HBc positive; 22 of those 115 had detectable occult HBV, and genotype D accounted for 81% of OBI-positive cases. In the pregnancy cohort, two of 200 women were HBsAg positive; among 182 HBsAg-negative women with anti-HBc results, 47 were anti-HBc positive, and 37 of those 47 had detectable HBV DNA. Both overt infections and 36 of 37 DNA-positive occult infections were genotype D.⁸⁹

6. Why Genotyping Method Changes the Result

The 2024 RFLP-based report is therefore not “wrong” merely because it differs from earlier sequence studies. It may be detecting within-host mixtures that consensus sequencing under-recognizes, but it may also be vulnerable to restriction-site variation and classification ambiguity. The scientifically defensible response is orthogonal validation: retest representative A/E/F mixed-pattern specimens using genotype-specific quantitative assays and high-depth whole-genome sequencing, include negative and contamination controls, define minority-variant thresholds, and publish read-level evidence. Until then, the RFLP result should remain a separate assay-defined finding rather than overturning the sequence-based national picture.¹³

7. Clinical and Public-Health Meaning

International literature links some HBV genotypes and variants with differences in HBeAg seroconversion, disease progression, interferon responsiveness and hepatocellular-carcinoma risk. These associations are not universal and are far better established for some Asian genotype comparisons than for Ethiopian A1-versus-D lineages. Extrapolation without Ethiopian longitudinal outcome data risks biological overstatement.¹⁶

For current clinical practice, treatment eligibility should continue to be determined by validated measures—HBV DNA, ALT and other liver tests, fibrosis or cirrhosis status, HBeAg where relevant, age, pregnancy, comorbidity, immunosuppression, family history and hepatocellular-carcinoma risk—under applicable clinical guidance. Genotyping is valuable for research, unusual diagnostic patterns, transmission investigation and selected specialist questions, but it is not a substitute for staging and monitoring.

Diagnostics and blood safety

Surface-gene variation can affect HBsAg antigenicity and, in some settings, diagnostic recognition. Ethiopian studies have reported major hydrophilic region substitutions and other surface changes, while OBI work demonstrates that HBsAg negativity does not always exclude persistent HBV DNA. These observations support local evaluation of diagnostic assays against circulating A1 and D lineages and strengthen the rationale for quality-assured nucleic-acid testing where feasible in blood safety. They do not imply that all observed substitutions produce vaccine escape or routine diagnostic failure; functional or validated assay evidence is required.

Drug-resistance substitutions

Polymerase substitutions reported in untreated and treated Ethiopian populations require careful interpretation. A sequence change may be a natural polymorphism, a compensatory change, an established resistance mutation or a low-confidence association. Treatment history, read quality, viral load, drug exposure and an accepted resistance database are necessary before labeling a variant clinically resistant. Findings from older lamivudine-exposed populations should not be generalized directly to contemporary high-barrier tenofovir-based care.

Vaccination

Nothing in the reviewed genotype distribution undermines universal hepatitis B vaccination. Current recombinant vaccines target HBsAg across genotypes and remain the cornerstone of prevention. The highest-priority actions remain timely birth-dose vaccination, completion of the infant series, testing and prophylaxis in pregnancy according to guidance, vaccination of susceptible adults at risk, safe blood, infection prevention and reliable linkage to care.

Genotype evidence in the era of simplified HBV care

The 2024 World Health Organization guidance expanded and simplified treatment eligibility, strengthened prevention of mother-to-child transmission, and emphasized improved access to HBV DNA testing, including point-of-care and reflex approaches. These priorities clarify the place of genotyping in public health: genotype surveillance is scientifically valuable, but it must not divert limited resources from diagnosis, fibrosis assessment, antiviral access, pregnancy prophylaxis, retention in care and liver-cancer surveillance. In routine care, viral genotype is generally not the central gateway to treatment eligibility.¹⁷

A rational Ethiopian programme would therefore operate on two connected tracks. The service-delivery track should maximize testing, prevention, clinical staging and treatment coverage. The reference-laboratory track should conduct strategically sampled sequencing to monitor lineages, diagnostic variants, antiviral-resistance patterns, recombination, occult infection and outbreaks. Integrating the two tracks through standardized metadata would convert isolated academic studies into a sustainable surveillance system.

WHO’s 2026 implementation handbook reinforces this programme logic by consolidating prevention, testing, treatment, service delivery and monitoring across the continuum of viral-hepatitis care. It emphasizes universal hepatitis B birth-dose vaccination, prevention of mother-to-child transmission, safe blood and injections, simplified and decentralized testing, molecular and reflex testing, person-centred treatment delivery, and robust strategic-information systems. For Ethiopia, sequencing will have its greatest public-health value when it improves case detection, assay performance, outbreak recognition, clinical linkage and equitable access rather than remaining an isolated research activity.¹⁸

From sequence observation to clinical claim: a required evidence ladder

A nucleotide change observed in a sequence is the beginning of interpretation, not its end. The first step is technical confirmation: adequate chromatogram or read support, exclusion of contamination and reproducibility. The second is annotation against genotype-matched references, because a residue unusual in one lineage may be normal in another. The third is functional evidence showing an effect on antigen expression, replication, drug susceptibility or antibody binding. The fourth is clinical association replicated in appropriately designed cohorts. Only after these levels align should a mutation be described as clinically consequential.

This evidence ladder is particularly important for claims of vaccine escape, diagnostic escape and antiviral resistance. Overcalling these labels can alarm patients, undermine vaccination and distort treatment decisions; under-recognition can also threaten blood safety and clinical care. The appropriate response is precise terminology: “substitution,” “candidate escape-associated variant,” “phenotypically validated variant,” or “clinically associated resistance mutation,” depending on the evidence actually available.

An evidence-certainty map for the Ethiopian findings

Why amplification failure is epidemiological information

Samples that fail PCR or sequencing are often removed from genotype tables, but failure is not necessarily random. Very low viraemia is common in inactive infection and OBI; degraded specimens yield less amplifiable DNA; and primer mismatch can reduce amplification of particular lineages or variants. If genotype A amplifies more efficiently than genotype D—or the reverse—the observed distribution among successful sequences may differ from the distribution among all HBV-positive specimens. Every high-quality report should therefore describe primers, target coordinates, limit of detection, viral-load distribution, success rate and characteristics of successfully versus unsuccessfully sequenced specimens.

This principle explains why the molecular denominator deserves equal prominence with the recruitment denominator. A study may screen thousands of people, identify dozens of HBsAg-positive samples and ultimately classify only a fraction. The final percentage answers a narrow question: among the isolates that passed every selection and laboratory step, what lineages were observed? It does not automatically describe everyone initially screened.

Serotype, genotype and antigenic phenotype

Classical HBV serotypes are defined by antigenic determinants in HBsAg, including the shared “a” determinant and subtype-specific residues. Genotype and serotype are related but not identical classification systems: genotype describes genome-wide evolutionary ancestry, while serotype describes antigenic patterns of surface protein. Recombination, mutation and convergent changes can disrupt a simple one-to-one correspondence. Ethiopian reports of adw2 among A1 and ayw patterns among D are biologically coherent, but serotype inference from sequence is not equivalent to direct serological phenotyping.

The distinction matters for diagnostics and vaccination. A sequence-predicted amino-acid substitution near the major hydrophilic region may suggest altered antigenicity, yet the real effect depends on protein folding, secretion, glycosylation, epitope exposure and the antibodies used in a particular assay. Laboratory phenotype and clinical performance data are needed before an observed sequence is declared an escape mutant.

Precore, basal core promoter and pre-S variants

The precore G1896A substitution can create a premature stop codon that reduces or abolishes HBeAg production while replication may continue. Its compatibility is influenced by the nucleotide at position 1858 and therefore varies by genotype and subgenotype. Basal core promoter A1762T/G1764A substitutions can alter precore transcription and have been associated in international literature with virological and clinical phenotypes. Pre-S deletions can disturb envelope-protein balance, promote intracellular stress and occur more often in some advanced-disease settings. None of these observations means that the presence of a single variant predicts an individual outcome with certainty.

The Ethiopian whole-genome work reported G1896A frequently among genotype-D strains, basal core promoter double substitutions in subsets of both A and D, and several pre-S deletions. These signals justify larger genotype-stratified studies linked to HBeAg, viral load, fibrosis and longitudinal outcomes. Cross-sectional molecular detection alone cannot determine when the mutation arose, whether it drove disease progression or whether it simply became enriched as disease and immune selection evolved.

8. Evidence Limitations and Risk of Misinterpretation

The greatest error would be to average all published percentages and call the result Ethiopia’s genotype prevalence. Such a calculation would give unequal studies an artificial common meaning, ignore overlapping material, mix overt and occult infection, and treat RFLP patterns as equivalent to phylogenetic lineages. The honest conclusion is simultaneously strong and limited: A/A1 leads the conventional sequence evidence; D is second and diverse; the national proportions remain uncertain.

9. A National Research and Surveillance Agenda

1. Build a probability-informed sampling frame. Include every major region and city administration, rural and urban populations, age strata and clinically relevant groups without allowing convenience cohorts to define national estimates.
2. Use standardized epidemiological metadata. Report recruitment dates, residence, birthplace where appropriate, age, sex, pregnancy, HIV status, treatment exposure, HBsAg, HBeAg, anti-HBc, ALT, HBV DNA and liver-disease stage.
3. Adopt whole-genome sequencing strategically. Pair a large standardized major-genotype survey with whole genomes from every region, all rare calls, apparent mixtures, OBI cases and suspected recombinants.
4. Validate mixed infections. Confirm RFLP patterns by independent high-depth sequencing and report thresholds, strand support, replicate consistency and contamination controls.
5. Resolve D10 nomenclature. Expand the number and geography of complete D genomes and analyze them against current international reference sets and recombination-aware pipelines.
6. Investigate OBI rigorously. Use internationally aligned definitions, replicate extraction/PCR, adequate plasma volume, highly sensitive assays and independent laboratory confirmation.
7. Link genotype to longitudinal outcomes. Follow well-characterized cohorts for viral suppression, HBeAg and HBsAg loss, fibrosis progression, cirrhosis and HCC, with confounder adjustment.
8. Test diagnostic performance locally. Evaluate commonly used HBsAg and HBV-DNA platforms against Ethiopian A1, diverse D, low-level OBI and documented surface variants.
9. Deposit sequences and metadata responsibly. Public accession numbers, analysis code, reference panels and de-identified core metadata make classifications auditable and reusable.

10. Conclusion

Ethiopia’s molecular HBV literature tells a coherent first-order story and a complex second-order one. The coherent story is that genotype A—overwhelmingly A1—dominates conventional sequence-based evidence, while genotype D is the second major lineage. The complex story is that D contains multiple reported subgenotypes, including a distinctive Ethiopian cluster provisionally called D10; genotype E occurs at low frequency in at least one sequence dataset; occult-infection cohorts in Gondar show pronounced D predominance; and a large RFLP study has raised an unresolved mixed-infection signal.

These findings make Ethiopia an important setting for African HBV phylogeography and genomic surveillance. They do not yet provide a precise national genotype map, demonstrate genotype-specific causation of disease, or justify genotype-directed routine treatment. The next advance will come not from a larger collection of incomparable percentages, but from representative sampling, whole genomes, validated detection of mixtures, rigorous OBI methods and longitudinal clinical linkage.

Publication Information and Declarations

References